ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "SYK"

  • Abstract Number: 1319 • 2017 ACR/ARHP Annual Meeting

    TAS05567 Is a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor That Attenuates Disease Severity in Animal Models of Autoimmune Diseases

    Hiroaki Hayashi, Ryuusuke Kaneko, Manabu Tayama, Shunsuke Demizu, Daichi Akasaka, Hiroki Irie, Aki Kawagishi, Yoshio Ogino, Teruhiro Utsugi, Eiji Sasaki and Yoshikazu Iwasawa, TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan

    Background/Purpose: Spleen tyrosine kinase (Syk) is a non-receptor cytoplasmic tyrosine kinase. B-cell receptor (BCR) and Fc receptor-mediated syk signaling pathways lead to activation of several…
  • Abstract Number: 1329 • 2017 ACR/ARHP Annual Meeting

    A Quantitative Framework for Evaluating Drug Combination Treatment in Rat Collagen-Induced-Arthritis Model

    Amy Meng1, Julie Di Paolo2, Shringi Sharma3 and Anita Mathias3, 1Clinical Pharmacology, Gilead Sciences, Foster City, CA, 2Immunology and Inflammation Biology, Gilead Sciences, Foster City, CA, 3Gilead Sciences, Foster City, CA

    Background/Purpose: Filgotinib (FIL), a JAK1 inhibitor, and GS-9876, a SYK inhibitor, are currently being evaluated as once-daily monotherapy in subjects with rheumatoid arthritis (RA). A…
  • Abstract Number: 1454 • 2016 ACR/ARHP Annual Meeting

    Combination of the SYK Inhibitor, GS-9876, with a JAK Inhibitor Increases Efficacy in a Chronic Rat Model of Collagen-Induced Arthritis

    Julie Di Paolo1, David Alonzo2, Christian Franci3, Terry Gentzler1, Li Li4, Bernard Murray5 and Jim Zheng5, 1Biology, Gilead Sciences, Foster City, CA, 2FPD, Gilead Sciences, Foster City, CA, 3Biology, Gilead Sciences, Foster, CA, 4Gilead Sciences, South San Francisco, CA, 5DMPK, Gilead Sciences, Foster City, CA

    Background/Purpose:   Here we demonstrate that 1) the single agent activity of GS-9876 is efficacious in a late stage rat model of collagen-induced arthritis (CIA);…
  • Abstract Number: 1594 • 2016 ACR/ARHP Annual Meeting

    First-in-Human Pharmacokinetics and Safety of Escalating Single- and Multiple-Doses of GS-9876, a Novel, Oral SYK Inhibitor, in Healthy Subjects

    Michael Dolton1, Franziska Matzkies2, Kevin Currie3, Julie Di Paolo4, Lu Wang3, Hao Zheng3, Srini Ramanathan3 and Jeffrey Silverman3, 1Clinical Pharmacology, Gilead Sciences, Inc, Foster City, CA, 2Gilead Sciences, Inc, Foster City, CO, 3Gilead Sciences, Inc, Foster City, CA, 4Biology, Gilead Sciences, Foster City, CA

    Background/Purpose: Spleen Tyrosine Kinase (SYK) mediates immunoreceptor signaling in a range of hematopoietic cells important for the initiation and progression of inflammatory diseases such as…
  • Abstract Number: 2627 • 2016 ACR/ARHP Annual Meeting

    The Effect of Fostamatinib with Methotrexate on Circulating Biomarkers of Synovium, Cartilage and Bone Metabolism: Potential Utility for Clinical Development Decision Making in Rheumatoid Arthriti

    Adam Platt1, Anne C. Bay-Jensen2, Martin Braddock3, Martin Jenkins4, Kishwar Musa5, Christian S. Thudium6, Cecilie F. Kjelgaard-Petersen6, Emma Graham3, Sue Keeler3, Gill Slynn3, Michael Weinblatt7 and Morten Asser Karsdal2, 1Diagnostic Development, AstraZeneca, Cheshire, United Kingdom, 2Rheumatology, Nordic Bioscience, Herlev, Denmark, 3AstraZeneca, Macclesfield, United Kingdom, 4Research & Development, AstraZeneca, Macclesfield, United Kingdom, 5Laboratory, Nordic Bioscience, Herlev, Denmark, 6Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 7Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Fostamatinib was developed for the treatment of RA and improved signs and symptoms of RA 1, but did not improve modified Total Sharp Score…
  • Abstract Number: 1093 • 2015 ACR/ARHP Annual Meeting

    Activation of Syk-Btk Signal in Peripheral Blood B Cells in Patients with Rheumatoid Arthritis: A Potential Target for Abatacept Therapy

    Shigeru Iwata1, Shingo Nakayamada2, Shunsuke Fukuyo1, Sheau-Pey Wang1, Satoshi Kubo2, Maiko Yoshikawa1, Kazuyoshi Saito3 and Yoshiya Tanaka3, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 3The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan

    Background/Purpose: B cells play a pivotal role in the pathogenesis of autoimmune diseases. Although Syk function as a key molecule in BCR signaling, the pathological…
  • Abstract Number: 2458 • 2014 ACR/ARHP Annual Meeting

    Targeting IL-6, JAK or SYK? : An Analysis of Transcriptome Alteration in Peripheral Blood By RA Treatments

    Yoshinobu Koyama1, Motohiko Tanino2, Shuji Nagano3, Toshiyuki Ota3 and Toshie Higuchi1, 1Center for Autoimmune Diseases, Division of Rheumatology, Japan Red Cross Okayama Hospital, Okayama, Japan, 2DNA Chip Research Inc., Yokohama, Japan, 3Center for Rheumatic Diseases, Iizuka Hospital, Iizuka, Japan

    Background/Purpose The advances in understanding of the molecular nature of immune cell receptors enabled to offer new oral, targeted therapies. Tofacitinib (TOF) is the first…
  • Abstract Number: 716 • 2013 ACR/ARHP Annual Meeting

    The Active Metabolite Of Spleen Tyrosine Kinase Inhibitor Fostamatinib Abrogates The T Cell Priming Capacity Of Dendritic Cells

    Andrew Platt1, Ross McQueenie1, Robert Benson2, John Butcher1, Martin Braddock3, James M. Brewer4, Iain B. McInnes1 and Paul Garside1, 1Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 3AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, 4Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Spleen tyrosine kinase (SYK) is a core signaling protein that drives inflammatory responses and is fundamental to the propagation of signals via numerous immune-receptors…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences